Landfar Bio-medicine Co., Ltd

Informe acción SZSE:000504

Capitalización de mercado: CN¥3.5b

Landfar Bio-medicine Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Landfar Bio-medicine's earnings have been declining at an average annual rate of -50.7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.03% per year.

Información clave

-50.7%

Tasa de crecimiento de los beneficios

-50.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 11.3%
Tasa de crecimiento de los ingresos-0.03%
Rentabilidad financiera-20.0%
Margen neto-29.8%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Oct 21
There's Reason For Concern Over Landfar Bio-medicine Co., Ltd's (SZSE:000504) Massive 37% Price Jump

Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Jun 09
Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Apr 17
Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Mar 01
Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Desglose de ingresos y gastos

Cómo gana y gasta dinero Landfar Bio-medicine. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SZSE:000504 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 24124-3710713
30 Jun 24123-2811312
31 Mar 24128-2911313
31 Dec 23137-2811613
30 Sep 23149-1312910
30 Jun 23161-2413110
31 Mar 23170-1513110
31 Dec 22200-1213710
30 Sep 22210-101219
30 Jun 22199-111219
31 Mar 22188-201279
01 Jan 22157-191229
30 Sep 211743988
30 Jun 212014896
31 Mar 2119011775
31 Dec 201768695
30 Sep 20149355812
30 Jun 20116316412
31 Mar 20123247113
31 Dec 19134197616
30 Sep 19130-328018
30 Jun 19120-347319
31 Mar 19108-346818
31 Dec 1895-356016
30 Sep 18106-40667
30 Jun 1889-41576
31 Mar 1882-39474
31 Dec 1767-37413
30 Sep 177217312
30 Jun 177622290
31 Mar 176922290
31 Dec 166722280
30 Sep 1616-27270
30 Jun 1613-26250
31 Mar 1614-22220
31 Dec 1513-21210
30 Sep 1515-23220
30 Jun 1515-24210
31 Mar 1516-25230
31 Dec 1418-26250
30 Sep 142316230
30 Jun 142518240
31 Mar 142717220
31 Dec 132614220

Ingresos de calidad: 000504 is currently unprofitable.

Margen de beneficios creciente: 000504 is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 000504 is unprofitable, and losses have increased over the past 5 years at a rate of 50.7% per year.

Acelerando crecimiento: Unable to compare 000504's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 000504 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).


Rentabilidad financiera

Alta ROE: 000504 has a negative Return on Equity (-20.04%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado